Gujarat Themis Biosyn — 360° view

Gujarat Themis Biosyn, a company in the Pharmaceuticals industry, reported revenue of ₹44 crore and net profit of ₹11 crore for the June 2026 quarter.

Gujarat Themis Biosyn (NSE: GUJTHEM) closed at ₹352.70 on 20 Nov 2026, down 16.6% over the past year. Its market capitalisation is ₹4,590 crore and it trades at 235.8 times earnings.

Share price
₹352.70 (20 Nov 2026)
Market cap
₹4,590 Cr (20 Nov 2026)
P/E
235.77 (20 Nov 2026)
Revenue
₹44 Cr (June 2026 quarter)
Net profit
₹11 Cr (June 2026 quarter)
ROCE
18.1% (FY26)
ROE
17.4% (FY26)
Book value
₹26.4 (FY26)
Dividend yield
0.19% (last 12 months to 20 Nov 2026)
52-week high / low
₹470.05 / ₹225.05 (20 Nov 2026)
1-year return
-16.6% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: GUJTHEM

Incorporated in 1981, Gujarat Themis Biosyn Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.